Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Theravance announces positive results from a phase 2 study of TD-9855 in patients with fibromyalgia


Wednesday, 30 Apr 2014 04:05pm EDT 

Theravance Inc:Says positive results from a Phase 2 study of TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor (NSRI), in patients with fibromyalgia.Study demonstrated statistically significant and clinically meaningful improvements in the primary and secondary endpoints at the 20 mg dose of TD-9855 compared to placebo.5 mg dose did not meet statistical significance for the primary endpoint. Both doses were generally well tolerated. 

Company Quote

13.93
0.17 +1.24%
2:48pm EST